Cargando…
Safety Consequences of Off-Label Drugs Used for COVID-19
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934123/ https://www.ncbi.nlm.nih.gov/pubmed/33666902 http://dx.doi.org/10.1007/s40264-021-01056-0 |
| _version_ | 1783660761635094528 |
|---|---|
| author | Dasgupta, Nabarun |
| author_facet | Dasgupta, Nabarun |
| author_sort | Dasgupta, Nabarun |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7934123 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79341232021-03-05 Safety Consequences of Off-Label Drugs Used for COVID-19 Dasgupta, Nabarun Drug Saf Commentary Springer International Publishing 2021-03-05 2021 /pmc/articles/PMC7934123/ /pubmed/33666902 http://dx.doi.org/10.1007/s40264-021-01056-0 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Commentary Dasgupta, Nabarun Safety Consequences of Off-Label Drugs Used for COVID-19 |
| title | Safety Consequences of Off-Label Drugs Used for COVID-19 |
| title_full | Safety Consequences of Off-Label Drugs Used for COVID-19 |
| title_fullStr | Safety Consequences of Off-Label Drugs Used for COVID-19 |
| title_full_unstemmed | Safety Consequences of Off-Label Drugs Used for COVID-19 |
| title_short | Safety Consequences of Off-Label Drugs Used for COVID-19 |
| title_sort | safety consequences of off-label drugs used for covid-19 |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934123/ https://www.ncbi.nlm.nih.gov/pubmed/33666902 http://dx.doi.org/10.1007/s40264-021-01056-0 |
| work_keys_str_mv | AT dasguptanabarun safetyconsequencesofofflabeldrugsusedforcovid19 |